US7056916B2
(en)
|
2002-11-15 |
2006-06-06 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
Medicaments for the treatment of chronic obstructive pulmonary disease
|
KR101058696B1
(ko)
*
|
2002-12-10 |
2011-08-22 |
바이로켐 파마 인코포레이티드 |
후라비바이러스 감염의 치료 또는 예방을 위한 화합물과방법
|
GB0401334D0
(en)
|
2004-01-21 |
2004-02-25 |
Novartis Ag |
Organic compounds
|
DE102004003428A1
(de)
*
|
2004-01-23 |
2005-08-11 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
Neue langwirksame Beta-2-Agonisten, und deren Verwendung als Arzneimittel
|
US7220742B2
(en)
*
|
2004-05-14 |
2007-05-22 |
Boehringer Ingelheim International Gmbh |
Enantiomerically pure beta agonists, process for the manufacture thereof and use thereof as medicaments
|
GB0411056D0
(en)
|
2004-05-18 |
2004-06-23 |
Novartis Ag |
Organic compounds
|
GT200500281A
(es)
|
2004-10-22 |
2006-04-24 |
Novartis Ag |
Compuestos organicos.
|
GB0424284D0
(en)
|
2004-11-02 |
2004-12-01 |
Novartis Ag |
Organic compounds
|
GB0426164D0
(en)
|
2004-11-29 |
2004-12-29 |
Novartis Ag |
Organic compounds
|
GB0507577D0
(en)
|
2005-04-14 |
2005-05-18 |
Novartis Ag |
Organic compounds
|
GB0510390D0
(en)
|
2005-05-20 |
2005-06-29 |
Novartis Ag |
Organic compounds
|
CA2618089A1
(fr)
|
2005-08-08 |
2007-02-15 |
Argenta Discovery Ltd. |
Derives bicyclo[2,2]hept-7-ylamine et leurs utilisations
|
GB0516313D0
(en)
|
2005-08-08 |
2005-09-14 |
Argenta Discovery Ltd |
Azole derivatives and their uses
|
ES2530991T3
(es)
*
|
2005-08-15 |
2015-03-09 |
Boehringer Ingelheim Int |
Procedimiento para la obtención de betamiméticos
|
EP2532679B1
(fr)
|
2005-10-21 |
2017-04-12 |
Novartis AG |
Anticorps humains dirigés contre l'IL -13 et utilisations thérapeutiques
|
GB0601951D0
(en)
|
2006-01-31 |
2006-03-15 |
Novartis Ag |
Organic compounds
|
US8258141B2
(en)
|
2006-04-21 |
2012-09-04 |
Novartis Ag |
Organic compounds
|
ATE502943T1
(de)
|
2006-09-29 |
2011-04-15 |
Novartis Ag |
Pyrazolopyrimidine als pi3k-lipidkinasehemmer
|
KR20090075714A
(ko)
|
2006-10-30 |
2009-07-08 |
노파르티스 아게 |
소염제로서의 헤테로시클릭 화합물
|
EA201101492A1
(ru)
*
|
2006-11-15 |
2012-09-28 |
Вирокем Фарма Инк. |
Аналоги тиофена для лечения или предупреждения флавивирусных инфекций
|
DE602007011670D1
(de)
|
2007-01-10 |
2011-02-10 |
Irm Llc |
Verbindungen und zusammensetzungen als kanal-aktivierende proteasehemmer
|
EA200901489A1
(ru)
|
2007-05-07 |
2010-04-30 |
Новартис Аг |
Органические соединения
|
AU2008334629B2
(en)
|
2007-12-10 |
2012-04-12 |
Novartis Ag |
Organic compounds
|
WO2009087224A1
(fr)
|
2008-01-11 |
2009-07-16 |
Novartis Ag |
Pyrimidines utilisés en tant qu'inhibiteurs de kinase
|
EP2300010B1
(fr)
|
2008-06-10 |
2015-03-04 |
Novartis AG |
Dérivés de pyrazine en tant que bloqueur du canal sodique epithelial
|
US8236786B2
(en)
|
2008-08-07 |
2012-08-07 |
Pulmagen Therapeutics (Inflammation) Limited |
Respiratory disease treatment
|
NZ594157A
(en)
|
2008-12-30 |
2013-07-26 |
Pulmagen Therapeutics Inflammation Ltd |
Sulfonamide compounds for the treatment of respiratory disorders
|
TW201031406A
(en)
|
2009-01-29 |
2010-09-01 |
Novartis Ag |
Substituted benzimidazoles for the treatment of astrocytomas
|
WO2010150014A1
(fr)
|
2009-06-24 |
2010-12-29 |
Pulmagen Therapeutics (Inflammation) Limited |
Glitazones 5r-5–deutérés pour le traitement de maladies respiratoires
|
US8389526B2
(en)
|
2009-08-07 |
2013-03-05 |
Novartis Ag |
3-heteroarylmethyl-imidazo[1,2-b]pyridazin-6-yl derivatives
|
MX2012001838A
(es)
|
2009-08-12 |
2012-02-29 |
Novartis Ag |
Compuestos de hidrazona heterociclico y sus usos para tratar cancer e inflamacion.
|
MY162604A
(en)
|
2009-08-17 |
2017-06-30 |
Intellikine Llc |
Heterocyclic compounds and uses thereof
|
IN2012DN01453A
(fr)
|
2009-08-20 |
2015-06-05 |
Novartis Ag |
|
CA2777245A1
(fr)
|
2009-10-22 |
2011-04-28 |
Vertex Pharmaceuticals Incorporated |
Compositions destinees au traitement de la mucoviscidose et d'autres maladies chroniques
|
GB0918924D0
(en)
|
2009-10-28 |
2009-12-16 |
Vantia Ltd |
Azaindole derivatives
|
GB0918923D0
(en)
|
2009-10-28 |
2009-12-16 |
Vantia Ltd |
Aminothiazole derivatives
|
GB0918922D0
(en)
|
2009-10-28 |
2009-12-16 |
Vantia Ltd |
Aminopyridine derivatives
|
WO2011098746A1
(fr)
|
2010-02-09 |
2011-08-18 |
Pulmagen Therapeutics (Inflammation) Limited |
Sels d'addition acide cristallins de l'énantiomère (5r) de la pioglitazone
|
GB201002243D0
(en)
|
2010-02-10 |
2010-03-31 |
Argenta Therapeutics Ltd |
Respiratory disease treatment
|
GB201002224D0
(en)
|
2010-02-10 |
2010-03-31 |
Argenta Therapeutics Ltd |
Respiratory disease treatment
|
US8247436B2
(en)
|
2010-03-19 |
2012-08-21 |
Novartis Ag |
Pyridine and pyrazine derivative for the treatment of CF
|
UY33597A
(es)
|
2010-09-09 |
2012-04-30 |
Irm Llc |
Compuestos y composiciones como inhibidores de la trk
|
WO2012034095A1
(fr)
|
2010-09-09 |
2012-03-15 |
Irm Llc |
Composés et compositions comme inhibiteurs de trk
|
US8372845B2
(en)
|
2010-09-17 |
2013-02-12 |
Novartis Ag |
Pyrazine derivatives as enac blockers
|
EP2673277A1
(fr)
|
2011-02-10 |
2013-12-18 |
Novartis AG |
Composés de [1, 2, 4]triazolo [4, 3 -b]pyridazine en tant qu'inhibiteurs de la tyrosine kinase c-met
|
US9127000B2
(en)
|
2011-02-23 |
2015-09-08 |
Intellikine, LLC. |
Heterocyclic compounds and uses thereof
|
WO2012116217A1
(fr)
|
2011-02-25 |
2012-08-30 |
Irm Llc |
Composés et compositions en tant qu'inhibiteurs de trk
|
US8883819B2
(en)
|
2011-09-01 |
2014-11-11 |
Irm Llc |
Bicyclic heterocycle derivatives for the treatment of pulmonary arterial hypertension
|
EP2755976B1
(fr)
|
2011-09-15 |
2018-07-18 |
Novartis AG |
3-(quinolin-6-ylthio)-[1,2,4]triazolo[4,3-a]pyradines substituées en position 6 à activité tyrosine kinase
|
WO2013038381A1
(fr)
|
2011-09-16 |
2013-03-21 |
Novartis Ag |
Dérivés d'amide pyridine/pyrazine
|
WO2013038373A1
(fr)
|
2011-09-16 |
2013-03-21 |
Novartis Ag |
Dérivés pyrimidinamides
|
EP2755967B1
(fr)
|
2011-09-16 |
2015-10-21 |
Novartis AG |
Composés hétérocycliques destinés au traitement de la mucosviscidose
|
WO2013038390A1
(fr)
|
2011-09-16 |
2013-03-21 |
Novartis Ag |
Hétérocyclyle carboxamides n-substitués
|
WO2013038378A1
(fr)
|
2011-09-16 |
2013-03-21 |
Novartis Ag |
Dérivés pyridinamides
|
EP2793893A4
(fr)
|
2011-11-23 |
2015-07-08 |
Intellikine Llc |
Régimes de traitement améliorés utilisant des inhibiteurs de mtor
|
US8809340B2
(en)
|
2012-03-19 |
2014-08-19 |
Novartis Ag |
Crystalline form
|
CN104245701A
(zh)
|
2012-04-03 |
2014-12-24 |
诺华有限公司 |
有酪氨酸激酶抑制剂的组合产品和其应用
|
US9073921B2
(en)
|
2013-03-01 |
2015-07-07 |
Novartis Ag |
Salt forms of bicyclic heterocyclic derivatives
|
WO2014151147A1
(fr)
|
2013-03-15 |
2014-09-25 |
Intellikine, Llc |
Combinaison d'inhibiteurs de kinase et ses utilisations
|
TW201605450A
(zh)
|
2013-12-03 |
2016-02-16 |
諾華公司 |
Mdm2抑制劑與BRAF抑制劑之組合及其用途
|
US10112926B2
(en)
|
2014-04-24 |
2018-10-30 |
Novartis Ag |
Amino pyridine derivatives as phosphatidylinositol 3-kinase inhibitors
|
ES2667424T3
(es)
|
2014-04-24 |
2018-05-10 |
Novartis Ag |
Derivados de pirazina como inhibidores de fosfatidil-inositol-3-quinasa
|
BR112016024533A8
(pt)
|
2014-04-24 |
2021-03-30 |
Novartis Ag |
derivados de amino pirazina como inibidores de fosfatidilinositol 3-cinase ou sal, seu uso, e composição e combinação farmacêuticas
|
WO2016011658A1
(fr)
|
2014-07-25 |
2016-01-28 |
Novartis Ag |
Polythérapie
|
AU2015294889B2
(en)
|
2014-07-31 |
2018-03-15 |
Novartis Ag |
Combination therapy
|
WO2020250116A1
(fr)
|
2019-06-10 |
2020-12-17 |
Novartis Ag |
Dérivé de pyridine et de pyrazine pour le traitement de la fk, de la bpco et de la bronchiectasie
|
US20220306617A1
(en)
|
2019-08-28 |
2022-09-29 |
Novartis Ag |
Substituted 1,3-phenyl heteroaryl derivatives and their use in the treatment of disease
|